Promacta and Breo ellipta drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Promacta (eltrombopag olamine) and Breo ellipta (fluticasone furoate; vilanterol trifenatate). Common drug interactions include asthenia among females and aplastic anaemia among males.

The phase IV clinical study analyzes what interactions people have when they take Promacta and Breo ellipta. It is created by eHealthMe based on reports of 12 people who take the same drugs from the FDA, and is updated regularly.

What is Promacta?

Promacta has active ingredients of eltrombopag olamine. It is often used in idiopathic thrombocytopenic purpura (itp). eHealthMe is studying from 17,758 Promacta users. Check the latest studies of Promacta.

What is Breo ellipta?

Breo ellipta has active ingredients of fluticasone furoate; vilanterol trifenatate. It is often used in asthma. eHealthMe is studying from 37,362 Breo ellipta users. Check the latest studies of Breo ellipta.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

12 people who take Promacta and Breo ellipta together, and have interactions are studied.

Promacta and Breo ellipta drug interactions.

What are the common drug interactions of Promacta and Breo Ellipta, by gender? *:

female:

Asthenia (weakness)
Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
Back pain
Blood potassium decreased
Cardiovascular disorder (heart diseases)
Chest pain
Chronic kidney disease
Chronic left ventricular failure (long lasting functional impairment of left ventricle of heart)
Chronic respiratory failure
Contusion (a type of hematoma of tissue in which capillaries)

male:

Aplastic anaemia (blood disorder in which the body's bone marrow doesn't make enough new blood cells)
Death
Fluid retention (an abnormal accumulation of fluid in the blood)
Full blood count decreased
Platelet count decreased
Pulmonary congestion (congestion in the lungs)

What are the common drug interactions of Promacta and Breo Ellipta, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

Aplastic anaemia (blood disorder in which the body's bone marrow doesn't make enough new blood cells)
Fluid retention (an abnormal accumulation of fluid in the blood)
Full blood count decreased
Platelet count decreased
Pulmonary congestion (congestion in the lungs)

What are the existing conditions these people have? *

Pain: 2 people, 16.67%
Muscle Spasms (muscle contraction): 2 people, 16.67%
Multiple Myeloma (cancer of the plasma cells): 2 people, 16.67%
Indigestion: 2 people, 16.67%
Hypersensitivity Pneumonitis: 2 people, 16.67%
Cough: 2 people, 16.67%
Primary Myelofibrosis (primary disorder of the bone marrow): 1 person, 8.33%
Polycythaemia Vera (blood disorder in which the bone marrow makes too many red blood cells): 1 person, 8.33%
Aplastic Anemia: 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Promacta and Breo ellipta?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously